CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS [0.03%]
抗CTLA-4抗体伊匹单抗治疗脑转移的黑色素瘤患者有效
F Stephen Hodi,Darryl A Oble,Jan Drappatz et al.
F Stephen Hodi et al.
Background: A 63-year-old female presented to her primary physician with numbness and weakness in her left leg, which progressed over several days to involve her entire lower extremities. MRI of the spine and brain reveal...
Panagiotis A Konstantinopoulos,Dimitrios Spentzos,Stephen A Cannistra
Panagiotis A Konstantinopoulos
DNA-microarray technology has made it possible to simultaneously analyze the expression of thousands of genes in a small sample of tumor tissue. In epithelial ovarian cancer, gene-expression profiling has been used to provide prognostic inf...
Early postinduction intensification therapy is essential in childhood acute lymphoblastic leukemia [0.03%]
儿童急性淋巴细胞白血病早期强化治疗必不可少
Günter Henze
Günter Henze
Postinduction intensification therapy (PII) has been key to success in the treatment of many types of childhood cancer and has led to an increase in cure rates during the past 3 decades. This Practice Point commentary discusses the recent f...
Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer [0.03%]
-docetaxel化疗仍是去势抵抗性前列腺癌的标准治疗方案
Brian Schurko,William K Oh
Brian Schurko
This Practice point commentary discusses the findings of a randomized, multicenter, report published by Berthold et al, in which the results of the pivotal TAX 327 study are updated. The original TAX 327 study, published in 2004, randomly a...
VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia [0.03%]
促红细胞生成素药物治疗癌症相关性贫血的静脉血栓栓塞和死亡风险
Roxana S Dronca,David P Steensma
Roxana S Dronca
This Practice Point commentary examines a recent systematic review by Bennett et al. that summarized 51 controlled trials of the erythropoiesis-stimulating agents (ESAs) darbepoetin and epoetin in patients with cancer. The review focused ex...
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer [0.03%]
间断雄激素剥夺治疗应成为前列腺癌的标准疗法
Bostjan Seruga,Ian F Tannock
Bostjan Seruga
Mechanisms of Disease: signal transduction in lung carcinogenesis -- a comparison of smokers and never-smokers [0.03%]
疾病机制：肺癌发病过程中的信号传导——吸烟与不吸烟者的比较研究
Giannis Mountzios,Pierre Fouret,Jean-Charles Soria
Giannis Mountzios
Although smoking has been established as the most important cause of lung cancer, approximately 10% of patients with this malignancy have no history of smoking. The pathogenesis of tobacco-related lung carcinogenesis is becoming well charac...
Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer? [0.03%]
顺铂联合S-1与单用S-1相比用于晚期胃食管癌患者的效果如何？
Jaffer A Ajani
Jaffer A Ajani
The investigators of the recent phase III SPIRITS trial found that the addition of cisplatin to S-1 (a fourth generation oral fluoropyrimidine) provided a significant overall survival advantage (P = 0.04) over treatment with S-1 alone among...
Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC [0.03%]
疾病机制：Temsirolimus的生存益处证实mTOR在治疗晚期RCC中的作用
Robert A Figlin
Robert A Figlin
Temsirolimus is a specific inhibitor of mammalian target of rapamycin (mTOR) that is approved for the treatment of advanced renal cell carcinoma. mTOR is unique among antitumor drug targets because it is a convergence point for many signali...
Who should receive myeloablative therapy for diffuse large B-cell lymphoma? [0.03%]
谁应该接受清髓性治疗以治疗弥漫性大B细胞淋巴瘤？
Luciano Wannesson,Emanuele Zucca
Luciano Wannesson